Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of icarisid II or medical carrier of icarisid II to prevention and/or treatment of erectile dysfunction

A technology for erectile dysfunction and icariin, which is applied in the field of medicine, can solve the problems of insignificant improvement of pathological changes in an animal model of neurogenic ED, and achieve a remarkable effect.

Active Publication Date: 2018-08-14
北京东方百奥医药开发有限公司
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some studies have found that the effective rate of ED treatment is only 24-33%. [6-8]
In addition, the study found [9] , continuous administration of small doses of sildenafil did not significantly improve the pathological changes in animal models of neurogenic ED

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of icarisid II or medical carrier of icarisid II to prevention and/or treatment of erectile dysfunction
  • Application of icarisid II or medical carrier of icarisid II to prevention and/or treatment of erectile dysfunction
  • Application of icarisid II or medical carrier of icarisid II to prevention and/or treatment of erectile dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] (1) Experimental method:

[0054] (1) Experimental animals and groups

[0055] Ninety-six newborn 1-day-old male SD rats.

[0056] After 12 weeks, 12 rats were randomly selected as the sham operation group (Sham, laparotomy without injury to the cavernous nerve, n=12). The remaining 84 SD rats were injured bilateral cavernous nerves (see 2) to establish a neurogenic ED model; randomly selected 12 rats were fed with sildenafil, 1.25mg / kg / d; randomly selected 12 rats were fed with sildenafil Nafil, 2.5mg / kg / d; 12 randomly selected animals were fed with sildenafil, 5mg / kg / d; 12 randomly selected dogs were fed with icariside Ⅱ, 2.5mg / kg / d; randomly selected 12 rats were fed with icariin Ⅱ, 2.5 mg / kg / d; 12 rats were randomly selected and fed with icariin Ⅱ, 5 mg / kg / d; the remaining 12 rats were used as the model group (BCNI-3w).

[0057] (2) Establishment of neurogenic ED rat model:

[0058] After SD rats were born for 12 weeks, the ED animal model was established by inj...

Embodiment 2

[0077] Penile Erectile Function Assessment

[0078] Such as figure 1 Shown, daily feeding of sildenafil does not significantly improve the erectile function of the neurogenic ED rat model (VSBCNI-3w group); feeding ICAⅡ1.25mg / kg, 2.5mg / kg and 5mg / kg, It can significantly improve the erectile function of the neurogenic ED rat model (VSBCNI-3w group); and the ICAⅡ2.5mg / kg and 5mg / kg groups have significant differences compared with the ICAⅡ1.25mg / kg group; and the ICAⅡ2.5mg / kg kg and 5mg / kg group, ICAⅡ 5mg / kg group did not improve the penile erectile energy of rats significantly.

Embodiment 3

[0080] experimental method:

[0081] (1) Labeling systemic endogenous stem cells / precursor cells using the technique of labeling resident cells

[0082] Dissolve 50mg of EdU in 2.5ml of DMSO, add 2.5ml of sterilized deionized water, mix well, and keep warm in a 37-degree water bath. Within 12 hours after birth, the suckling mice were intraperitoneally injected with 50 μl of EdU solution at a dosage of 50 mg / kg.

[0083] (2) Experimental animals and grouping

[0084] Forty-eight newborn 1-day-old male SD rats were intraperitoneally injected with EdU-labeled endogenous stem / precursor cells.

[0085] After 12 weeks, 12 rats were randomly selected as the sham operation group (Sham, laparotomy without injury to the cavernous nerve, n=12). The remaining 48 SD rats were injured bilateral cavernous nerves (see 4) to establish neurogenic ED models; randomly selected 12 rats were fed with sildenafil, 2.5mg / kg / d; the remaining 12 rats were fed with epimedium Hyposide Ⅱ, 2.5mg / kg / d). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides application of icarisid II or a medical carrier of the icarisid II to prevention and / or treatment of erectile dysfunction, including the application of the icarisid II or the medical carrier of the icarisid II particularly to but not limited to the prevention and / or treatment of erectile dysfunction of mammal.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the application and application of icariside II or its pharmaceutically acceptable carrier in erectile dysfunction, especially but not limited to the prevention and / or treatment of erectile dysfunction in mammals. Background technique [0002] In 1995, there were approximately 152 million ED patients worldwide, and this number is expected to increase to 322 million by 2025 [1] . According to statistics, the prevalence of ED in middle-aged men (40.2±5.8 years old) in Beijing and other areas of my country is as high as 40.2%. [2] . At present, oral PDE5 inhibitors (such as sildenafil, tadalafil) are the first-choice therapy for clinical treatment of ED, but ED patients with different etiologies have different responses to drugs. For example, ED patients with hypogonadism have the best effect of taking PDE5 inhibitors after receiving testosterone replacement therapy (effective rate: 85%), w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P15/10C12P19/60C12R1/885
CPCA61P15/10A61K31/7048C12P19/60C12P17/06
Inventor 刘接卿辛华顾静良姚正
Owner 北京东方百奥医药开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com